详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

EGFR-216G/T polymorphism as a predictor of clinical outcomes in advanced non-small cell lung cancer patients treated with EGFR-TKIs: a meta-analysis

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

出处：

ISSN：

关键词： EGFR 216G/T polymorphism NSCLC EGFR-TKIs

摘要：

Epidermal growth factor receptor gene -216G/T polymorphism has been implicated to be associated with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with EGFR-TKIs. However, the results are inconsistent due to the limitation of sample size. Based on previous studies; we conducted this meta-analysis aiming to provide more reliable results. A total of 6 studies, including 955 advanced NSCLC patients treated with EGFR-TKIs, were included. Review Manager 5.3 was used to perform the statistical analysis. The response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were included in our outcomes. Our study suggested that TT+GT genotypes showed association with higher response rates (GT+TT vs. GG RR = 2.08; 95% CI = 1.53-2.82; P<0.00001), higher disease control rate (GT+TT vs. GG RR = 1.23; 95% CI = 1.08-1.40; P = 0.002), longer progression-free survival (GT+TT vs. GG HR = 0.80; 95% CI = 0.67-0.95; P = 0.009) and longer overall survival (GT+TT vs. GG HR = 0.80; 95% CI = 0.66-0.96; P = 0.01) than GG homozygote. The combined results based on all included studies suggested that EGFR-216G/T polymorphism could be a potential biomarker for EGFR-TKIs in advanced NSCLC patients.

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

JCR分区：

出版当年[2014]版：

Q4 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q4 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 0.2 最新[2023版] 0.2 最新五年平均 1.277 出版当年[2014版] 1.412 出版当年五年平均 1.422 出版前一年[2013版] 1.075 出版后一年[2015版]

第一作者：

第一作者单位： [1]Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

通讯作者：

通讯机构： [1]Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China [*1]Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hu-bei Province, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]EGFR-216G/T polymorphism as a predictor of clinical outcomes in advanced non-small cell lung cancer patients treated with EGFR-TKIs: a meta-analysis [2]EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases [3]EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs [4]EGFR-TKIs resistance via EGFR-independent signaling pathways [5]The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC [6]Anti-VEGF therapy sensitizes EGFR/MET co-altered NSCLC cells to TKIs via inhibiting the VEGF/ERK/MET pathway [7]Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging [8]Monitoring the response of PD-Li expression to EGFR-TKIs in NSCLC xenografts by immuno-P1-47T imaging [9]EGFR-TKIs plus Stereotactic Body Radiation Therapy (SBRT) for Stage IV Non-small Cell Lung Cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study [10]Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases